Elicio Therapeutics (ELTX) presented updated results from its phase 1 AMPLIFY-201 clinical trial of ELI-002 in individuals with mutant KRAS-driven colorectal or pancreatic cancer.
ELI-002 is designed as an off-the-shelf vaccine to target KRAS mutations, a driver in approximately 25% of all solid tumors.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com